LYVGEN BIOPHARMA
LYVGEN BIOPHARMA
Industry:
Biopharma Health Care Medical
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.lyvgen.com
Total Employee:
11+
Status:
Active
Contact:
021-50663360
Email Addresses:
[email protected]
Total Funding:
40 M USD
Technology used in webpage:
SPF Microsoft Azure DNS DMARC Alibaba HiChina DNS Coremail
Current Employees Featured
Founder
Investors List
FTZ Fund
FTZ Fund investment in Series C - Lyvgen Biopharma
Longmen Capital
Longmen Capital investment in Series C - Lyvgen Biopharma
Chengwei Capital
Chengwei Capital investment in Series C - Lyvgen Biopharma
IDG Capital
IDG Capital investment in Series C - Lyvgen Biopharma
Winfair Global
Winfair Global investment in Series B - Lyvgen Biopharma
6 Dimensions Capital
6 Dimensions Capital investment in Series B - Lyvgen Biopharma
Official Site Inspections
http://www.lyvgen.com
- Host name: catl.com
- IP address: 203.107.45.167
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Lyvgen Biopharma"
Lyvgen Biopharma - Crunchbase Company Profile & Funding
Organization. Lyvgen Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Lyvgen Biopharma is a Healthcare …See details»
礼进生物 Lyvgen Biopharma - Lyvgen Biopharma Website 礼进生 …
Lyvgen’s mission aligns with my life-long passion. Ever since college, my education and work experiences have been focused on the drug discovery and development. Lyvgen’s culture is …See details»
礼进生物 Lyvgen Biopharma
“Lyvgen is a startup biopharma company committed to deliver innovative medicines to help millions of cancer patients around the world. Its mission aligns well with my life-long passion. …See details»
Lyvgen Company Profile 2024: Valuation, Funding & Investors
Lyvgen General Information Description. Developer of healthcare platform intended to offer immune-oncology research and development services. The company's platform helps in …See details»
Lyvgen Biopharma - Overview, News & Similar companies
Jun 3, 2021 Lyvgen Biopharma contact info: Phone number: +86 2150663350 Website: www.lyvgen.com What does Lyvgen Biopharma do? Lyvgen is a biopharmaceutical company …See details»
Lyvgen Biopharma - Funding, Financials, Valuation & Investors
Lyvgen Biopharma is a Healthcare Company. How much funding has this organization raised over time? ShowSee details»
Jieyi Wang - Fouder and CEO - Lyvgen Biopharma | LinkedIn
Founder and CEO, Lyvgen Biopharma · R & D of innovative biotherapeutics · Experience: Lyvgen Biopharma · Education: Stony Brook University Graduate School · Location: San Francisco …See details»
Organization | Lyvgen Biopharma Holdings Limited - Purdue …
Organization Overview. First Clinical Trial. 2019 NCT04130542. First Marketed Drug. None First NDA Approval. None ... Lyvgen Biopharma | Lyvgen Biopharma Holdings Limited Active …See details»
Lyvgen Biopharma Company Profile - Office Locations ... - Craft
Lyvgen Biopharma is a company developing cancer immunotherapy drugs. The company is creating antibodies including PD-1 antibody SSI-361 and a set of proprietary co-stimulation …See details»
Lyvgen Pharma - VentureRadar
Lyvgen Biopharma is a pioneering biotechnology company focused on developing next-generation immunotherapies for cancer treatment. Their clinical development candidates …See details»
Lyvgen Biopharma - LinkedIn
Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAbâ„¢ functional platform creates agonist antibodies (Abs) with tumor-localized ...See details»
News - Lyvgen Biopharma Website 礼进生物 英文官网
Jun 4, 2021 Lyvgen Biopharma (Suzhou) officially opened in BioBAY, Suzhou, China. Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi …See details»
Lyvgen Announces Clinical Trial Collaboration With MSD
Jun 10, 2020 About Lyvgen (www.lyvgen.com) Lyvgen is a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics. Lyvgen’s most advanced programs …See details»
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol …
Nov 27, 2022 Lyvgen's focus on immune agonists is widely applicable for most cancer indications. Our xLinkAb platform helps achieve a balance between safety and efficacy, which …See details»
Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB …
Jun 4, 2021 Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting. June 04, 2021 09:00 AM Eastern Daylight …See details»
liuxiaofeng - Lyvgen Biopharma Website 礼进生物 英文官网
"Lyvgen is a mission-driven organization with incredible preclinical and clinical pipeline to allow me to bring new innovations into drug product development, which is well aligned with my …See details»
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol …
Dec 4, 2022 LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to …See details»
Living Innovation - Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Our world-leading cross-linking antibody (xLinkAbâ„¢) functional platform creates new biology and molecules with …See details»
Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB …
The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA® …See details»